no doubt the CR rates of >80% from cilta-cel are impressive, but CAR-T therapies remain prohibitively expensive so it’s less clear whether these will ultimately become the SoC for multiple myeloma. Quick google of cilta-cel has a single dose costing upwards of $300,000 USD. So it would appear to me that a combo of carfilzomib and Zantrene would have a place in treatment algorithms given it would be substantially cheaper. Would need quite a bit of economic analysis and more data from cilta-cel trials before we could make a guess either way.
no doubt the CR rates of >80% from cilta-cel are impressive, but...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.52 |
Change
0.000(0.00%) |
Mkt cap ! $254.2M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 323 | $1.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.55 | 2999 | 1 |
View Market Depth
| Last trade - 07.43am 22/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.56 |
Change
0.000 ( 2.98 %) |
||||
| Open | High | Low | Volume | ||
| $1.53 | $1.56 | $1.53 | 194 | ||
| Last updated 10.20am 22/05/2024 ? | |||||
| RAC (ASX) Chart |
Day chart unavailable